SCHEMBL13617971

SCHEMBL13617971

CC(F)(F)c1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.45
TSHR P16473 3/20 0.43
LMNA P02545 1/20 0.43
HSD11B1 P28845 3/20 0.41
CYP19A1 P11511 1/20 0.40
PDK1 Q15118 4/20 0.38
PDK2 Q15119 4/20 0.38
PDK3 Q15120 4/20 0.38
PDK4 Q16654 4/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1A P35348 1/20 0.37
OPRK1 P41145 1/20 0.37
KCNH2 Q12809 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
P2RX7 Q99572 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KCNA3 P22001 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17109738 0.81 KCNN4 (0.42) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL4601609 0.81 KCNN4 (0.42) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL21497368 0.81 ALDH1A1 (0.43) TSHRLMNAHSD11B1HTR2CALDH1A1
SCHEMBL7571745 0.79 KCNN4 (0.48) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL5966718 0.79 KCNN4 (0.48) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL15998876 0.79 ALDH1A1 (0.43) TSHRLMNAHSD11B1HTR2CALDH1A1
SCHEMBL78489 0.79 TSHR (0.50) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL809831 0.79 KCNN4 (0.48) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL29467226 0.79 KCNN4 (0.48) KCNN4TSHRLMNAHSD11B1CYP19A1
SCHEMBL117692 0.79 KCNN4 (0.48) KCNN4TSHRLMNAHSD11B1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790858-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY Glucox Biotech AB (SE) 2021-03-17 EP disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed
US-20150266856-A1 RORGamma Modulators EXELIXIS, INC. 2015-09-24 US disclosed
EP-1499311-B1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266856-A1 RORGamma Modulators RORB, RORA, RORC KCNN4 2530/4885TSHR 227/4885LMNA 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.